Carasent, Q3 2021 - Presentation

Interim report Q3 2021

27October2021

Disclaimer

Certain statements made in this Presentation may include forward-looking statements. These statements relate to the Company's expectations, beliefs, intentions or strategies regarding the future. The forward-looking statements reflect the Company's current views and assumptions with respect to future events and are subject to risks and uncertainties.

All though the Company believes that its expectations and the Presentation are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in the Presentation.

Carasent ASA is making no representations or warranty, expressed or implied, as to the accuracy, reliability or completeness of the Presentation, and neither Carasent ASA, nor any of its directors, officers, employees or advisors will have any liability to you or any other person resulting from your use.

Agenda

1. Q3 highlights
2. Business and market update
3. Financial review
4. Outlook

Q3 2021 summary

1 Revenue growth of 109%

Revised guidance to 30 - 35% organic growth for Evimeria and Avans Soma

3 (from 35%) due to delayed revenues

from new customers

2

4

Organic growth of 26% for the group and 29% of Evimeria & Avans Soma

Continued strong order inflow and

backlog

5		Raised NOK 420 million in private	6	Active pipeline of new M&A
	placement	opportunities

Carasent at a glance

• Cloud-basedproprietary medical record software solution for the private healthcare segment

▪ Broad ecosystem of integrated third party services

▪ Two acquisitions completed during the last year, including Avans Soma in December 2020 and Metodika in May 2021

▪ Significant opportunity to expand organically and through M&A:

▪ New products and services

▪ New geographies

▪ New segments

NOK 117m

NOK 139m

811

LTM revenues1

ARR per Sep-21

Units